The Innovation and Technology Payment programme speeds up the implementation and roll-out of proven and affordable technology, and eliminates financial and procurement obstacles so the NHS can adopt innovative medical devices, diagnostics, and digital products.
Two Roche blood tests have been accepted for the ITP programme, the Elecsys immunoassay sFlt-1/PlGF ratio test to help rule out pre-eclampsia in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus six days of gestation; and the Elecsys Troponin T highsensitive assay for the early rule out of nonSTsegmentelevation myocardial infarction or heart attack, in people presenting to an emergency department with chest pain and suspected acute coronary syndrome.
“Two Roche blood tests have been accepted for the ITP programme, the Elecsys immunoassay sFlt-1/PlGF ratio test and the Elecsys Troponin T highsensitive assay.“
Roche Diagnostics MD for UK and Ireland, Geoff Twist, said: “We are delighted that NHS England has accepted two of our products for the Innovation and Technology Payment programme, which provides ring-fenced funding for NHS Trusts to implement ground-breaking new products within their hospitals. The chosen Roche tests not only help healthcare professionals make quick and effective decisions and lead to long-term cost savings, but they also improve the patient experience. They include an immunoassay that can reliably rule out pre-eclampsia in pregnant women and a highly sensitive test, which can be used as an aid to help diagnose heart attacks and work out the risk of patients presenting with heart attacks. Both are already on the AAC list of rapid uptake products. Diagnostic testing accounts for 70% of clinical decisions, yet only makes up 1% of total NHS spend. At Roche, we have long called for mandated funding for NICE-approved diagnostic tests and we are delighted at this important step forward. It is especially exciting that two of our tests are the first in-vitro diagnostic products to receive ITP funding, and we look forward to seeing how this scheme continues in the future.”